Jenscare Scientific Co., Ltd. Announces Lux-Valve Plus Travel II Results Released At the 2023 TCT in the U.S
with severe tricuspid regurgitation. The TRAVEL II clinical trial enrolled 96 patients from 15 centers in China. The primary endpoint of the one-month clinical data released was the
composite event rate within 30-days after the procedures. As of the date of this announcement, nearly 500 implantation cases have been completed worldwide for transcatheter tricuspid valve replacement system products independently developed by the Company, and the longest follow-up record was over 5 years. The Company will continue to promote the commercialization of its products in China, Europe, the U.S. and the Asia-Pacific region.